Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure

NCT05100017

Status	RECRUITING
Phase	Not Applicable
Sponsor	Northwestern University
Enrollment	126 participants

Key Eligibility Criteria

Inclusion (5)

- Men and women between age 18-80 years who are diagnosed with stones who undergo ureteroscopy and ureteral stent placement.
- Patients who consent to the procedure will be randomized in 1:1 fashion by RedCAP either to the methocarbamol or oxybutynin arm. All patients will receive standard of care diclofenac, tamsulosin, and pyridium for pain control plus one of the study drugs.
- Willing to take only diclofenac (or tramadol for patients with contraindication to diclofenac), phenazopyridine, and acetaminophen for post stent placement discomfort.
- Willing to sign the Informed Consent Form.
- Able to read, understand, and complete patient questionnaires, pain texts, and medication diary.

Exclusion (7)

- Active, symptomatic urinary tract infection.
- Non-stone related ureteral obstruction or stricture.
- Procedural trauma or significant retained stone burden that could significantly contribute to patient discomfort.
- Spinal cord injuries (sensory loss due to injury).
- Non-stone related voiding dysfunction requiring supplemental bladder drainage tubes for more than 24 hours post operatively.

... and 2 more (see full listing online)

Locations (1 total)

Northwestern University, Chicago, Illinois, United States